|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||22.97 - 23.13|
|52 Week Range||9.02 - 23.35|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.63|
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.
NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * ZAGG, Inc. (NASDAQ:ZAGG) relating to its proposed acquisition by Evercel, Inc and its group.